About Careers Internship MedBlog Contact us

Lack of Proper Drug Safety Measures in Developing Countries Put Millions at Risk

by VR Sreeraman on September 7, 2007 at 5:12 PM
Lack of Proper Drug Safety Measures in Developing Countries Put Millions at Risk

Researchers have expressed concerns about the absence of appropriate monitoring programmes to assess drug safety in developing countries.

They fear that this could put the lives of millions of people in these countries at risk.


The developing countries have 90 pct of the world's disease burden and measures are being taken to ensure that the countries have a good supply of effective medicines.

Drug manufactures are being forced to remove legal and financial barriers to access without a proper drug safety monitoring system, according to the authors.

Ninety-six pct of the developing countries have pharmacovigilance systems, compared to just 25 pct of developing countries. In the analysis, writers said that the effects of new drugs cannot be compared by using the data compiled from the West because the severity of diseases and incidence trend are greatly influenced by the local environment.

The authors call for better collaboration between the academic community, the pharmaceutical industry and individual governments in order to create a single database, reports the British Medical Journal. Citing the success story of the public health, drug access campaigns and a regional surveillance system called the East African Network for Monitoring Anti-malarial Treatment, the authors suggest that there is a need for more of such partnerships.

However, the authors agree that setting up an own pharmacovigilance system would be a costly affair and many of the countries in the developing world do not have the resources for such a big investment. So, they suggest the World Health Organisation (WHO) should come up with a method to support pharmacovigilance in the developing world and this could include starting developing exchange programmes to increase local skill.

The article is published in the Sept 7 issue of British Medical Journal.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Lack of Proper Drug Safety Measures in Developing Countries Put Millions at Risk Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests